Outlook Therapeutics, Inc. (OTLK) stock
OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
$0.36−0.04 (-8.94%)
Close on Nov 17, 2026Market cap $87.79MP/E –Yield –
Outlook Therapeutics cash
Cash and short-term investments held at the end of each period.
Outlook Therapeutics's cash was $11.24M at Jun 30, 2026. For fiscal 2025 it was $8.08M, down 45.9% from the year before. Over ten years it grew -1.1% a year on average. The highest annual figure on record is $23.39M in fiscal 2023.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $8.08M | -45.9% |
| FY2024 | Sep 30, 2024 | $14.93M | -36.2% |
| FY2023 | Sep 30, 2023 | $23.39M | +34.5% |
| FY2022 | Sep 30, 2022 | $17.40M | +20.2% |
| FY2021 | Sep 30, 2021 | $14.48M | +15.5% |
| FY2020 | Sep 30, 2020 | $12.54M | +56.4% |
| FY2019 | Sep 30, 2019 | $8.02M | +366.7% |
| FY2018 | Sep 30, 2018 | $1.72M | -46.1% |
| FY2017 | Sep 30, 2017 | $3.19M | +35.4% |
| FY2016 | Sep 30, 2016 | $2.35M | -74.1% |
| FY2015 | Sep 30, 2015 | $9.07M | +286.1% |
| FY2014 | Sep 30, 2014 | $2.35M | – |
Quarterly cash
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | $11.24M | +26.3% |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | $7.75M | +2.5% |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | $8.68M | +52.2% |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | $8.08M | -45.9% |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | $8.90M | -72.2% |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | $7.56M | -84.0% |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | $5.70M | -44.9% |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | $14.93M | -36.2% |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | $32.02M | -5.0% |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | $47.23M | +8.3% |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | $10.36M | -80.2% |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | $23.39M | +34.5% |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | $33.71M | +29.5% |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | $43.63M | -37.8% |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | $52.34M | +261.5% |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | $17.40M | -11.7% |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | $26.02M | +367.3% |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | $70.15M | +459.6% |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | $14.48M | -39.6% |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | $19.69M | +323.2% |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | $5.57M | +317.6% |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | $12.54M | +56.4% |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | $23.95M | +70.8% |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | $4.65M | +2892.8% |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | $1.33M | +485.6% |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | $8.02M | +366.7% |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | $14.03M | +18.9% |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | $155.47K | -97.4% |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | $227.72K | -98.4% |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | $1.72M | -46.1% |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | $11.80M | +8332.3% |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | $5.94M | +7224.1% |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | $13.84M | +565.7% |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | $3.19M | +35.4% |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | $139.90K | -99.0% |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | $81.05K | -97.1% |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | $2.08M | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | $2.35M | – |
| Q3 FY2016CQ2 2016 | Jun 30, 2016 | $13.56M | – |
| Q2 FY2016CQ1 2016 | Mar 31, 2016 | $2.84M | – |
See a number that looks wrong?